Aptus Pharma FY26 Revenue Doubles, PAT Up 49.05%

Aptus Pharma Limited announced strong financial results for the half year and year ended March 31, 2026. The company reported a doubling of total revenue to ₹4,670.81 Lakhs, marking an 89.59% year-on-year growth. Net profit (PAT) increased by 49.05% to ₹461.99 Lakhs, while EBIDTA grew by 57.73% to ₹750.32 Lakhs. Aptus Pharma has expanded its product portfolio to over 250 formulations across chronic, acute, and wellness segments, operating on an asset-light model. The company's business is structured across Rx, OTC, Global, and ORBIT verticals, supported by a robust distribution network. Aptus Pharma aims for pan-India presence by 2030, manufacturing expansion, and global footprint, potentially exploring the retail pharmacy chain segment.